Could biomarkers in colorectal cancer help us to optimize adjuvant treatment?
Colorectal cancer patients may require adjuvant therapy depending on the biology and stage of the resected tumor. The ideal scenario is tailoring chemotherapy, obtaining the highest benefit. Use of the biomarker test provides robust data for clinical decision making, thereby delivering clinical benefits that improve patient outcomes and reduce healthcare costs. Prof David Kerr has devoted his career and experience to the study of biomarkers. In this lecture, he explains the process to validate the use of this test and its application in daily clinical practice.
